{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"Maximum tolerated dose (MTD) in both patients with BPDCN and AML. MTD defined as the highest dose level where less than 2/3 or 2/6 patients experienced a DLT","groups":[{"description":"First-line BPDCN participants who received at least 1 dose of Tagraxofusp either at 7µg/kg/day or 12 µg/kg/day in stage 1","id":"OG000","title":"First-line BPDCN"},{"description":"R/R BPDCN who received at least 1 dose of Tagraxofusp either at 12 µg/kg/day in Stage 1","id":"OG001","title":"R/R BPDCN"},{"description":"AML participants who received at least 1 dose of Tagraxofusp either at 7µg/kg/day, 9 µg/kg/day, 12 µg/kg/day or 16 µg/kg/day in Stage 1","id":"OG002","title":"Acute Myeloid Leukemia"}],"paramType":"NUMBER","populationDescription":"Patients with First-line Blastic Plasmacytoid Dendritic Cell Neoplasm, R/R Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia participating to stage 1 (dose-escalation)","reportingStatus":"POSTED","timeFrame":"21-day period after the first dose (cycle 1)","title":"MTD (Stage 1)","type":"PRIMARY","unitOfMeasure":"µg/kg/day"}